Cong Dai - Search Results

Year	Number of Results
2006	3
2007	1
2008	1
2009	1
2010	1
2011	2
2012	5
2013	6
2014	5
2015	17
2016	21
2017	17
2018	21
2019	28
2020	17
2021	22
2022	23
2023	24
2024	9

1

Combination therapy in inflammatory bowel disease: Current evidence and perspectives.

Dai C, Huang YH, Jiang M. Dai C, et al. Int Immunopharmacol. 2023 Jan;114:109545. doi: 10.1016/j.intimp.2022.109545. Epub 2022 Dec 9. Int Immunopharmacol. 2023. PMID: 36508920 Review.

2

Post-COVID-19 irritable bowel syndrome.

Dai C, Huang YH, Jiang M. Dai C, et al. Gut. 2024 Apr 5;73(5):869-870. doi: 10.1136/gutjnl-2023-329714. Gut. 2024. PMID: 36898830 No abstract available.

3

Efficacy of Mesalamine in Irritable Bowel Syndrome.

Dai C, Jiang M, Huang YH. Dai C, et al. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3462-3463. doi: 10.1016/j.cgh.2023.03.021. Epub 2023 Mar 29. Clin Gastroenterol Hepatol. 2023. PMID: 37001712 No abstract available.

4

Impact of malnutrition and sarcopenia on quality of life in patients with inflammatory bowel disease: A multicentre study.

Zhang Y, Zhang L, Gao X, Dai C, Huang Y, Wu Y, Zhou W, Cao Q, Jing X, Jiang H, Zhong Y, Zhu W, Wang X. Zhang Y, et al. Among authors: dai c. J Cachexia Sarcopenia Muscle. 2023 Dec;14(6):2663-2675. doi: 10.1002/jcsm.13341. Epub 2023 Oct 1. J Cachexia Sarcopenia Muscle. 2023. PMID: 37779327 Free PMC article.

5

Probiotics and irritable bowel syndrome.

Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Dai C, et al. World J Gastroenterol. 2013 Sep 28;19(36):5973-80. doi: 10.3748/wjg.v19.i36.5973. World J Gastroenterol. 2013. PMID: 24106397 Free PMC article. Review.

6

The prognostic value of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with diabetes or prediabetes: insights from NHANES 2005-2018.

Ding L, Zhang H, Dai C, Zhang A, Yu F, Mi L, Qi Y, Tang M. Ding L, et al. Among authors: dai c. Cardiovasc Diabetol. 2024 Feb 28;23(1):84. doi: 10.1186/s12933-024-02172-8. Cardiovasc Diabetol. 2024. PMID: 38419029 Free PMC article.

7

Fecal markers in the management of inflammatory bowel disease.

Dai C, Jiang M, Sun MJ. Dai C, et al. Postgrad Med. 2018 Sep;130(7):597-606. doi: 10.1080/00325481.2018.1503919. Epub 2018 Jul 31. Postgrad Med. 2018. PMID: 30063872 Review.

8

Venous Thromboembolism Following Discharge from Hospital Among Patients Admitted for Inflammatory Bowel Diseases.

Dai C, Huang YH. Dai C, et al. J Crohns Colitis. 2023 Mar 18;17(2):305. doi: 10.1093/ecco-jcc/jjac125. J Crohns Colitis. 2023. PMID: 36029298 No abstract available.

9

Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies.

Zheng DY, Wang YN, Huang YH, Jiang M, Dai C. Zheng DY, et al. Among authors: dai c. Int Immunopharmacol. 2024 Jan 5;126:111229. doi: 10.1016/j.intimp.2023.111229. Epub 2023 Nov 16. Int Immunopharmacol. 2024. PMID: 37977068

10

Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers.

Dou Z, Lin S, Dai C, Lu Y, Tian T, Wang M, Liu X, Zheng Y, Xu P, Li S, Sheng Q, Deng Y, Dai Z. Dou Z, et al. Among authors: dai c. Oncotarget. 2017 Jun 27;8(37):62703-62715. doi: 10.18632/oncotarget.18697. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 28977982 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

200 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year